National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 84900 [2024-24745]

Download as PDF 84900 Federal Register / Vol. 89, No. 206 / Thursday, October 24, 2024 / Notices lotter on DSK11XQN23PROD with NOTICES1 Individuals who plan to attend inperson or view the virtual meeting and need special assistance or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting can be accessed from the NIH Videocast at the following link: https:// videocast.nih.gov/. Name of Committee: Muscular Dystrophy Coordinating Committee. Date: November 22, 2024. Time: 9:00 a.m. to 4:00 p.m. ET. Agenda: The purpose of this meeting is to bring together committee members, representing government agencies, patient advocacy groups, other voluntary health organizations and people with lived experience to discuss topics of interest to the muscular dystrophy communities and renewal of the committee’s strategic plan, the Action Plan for the Muscular Dystrophies. The committee will discuss gaps and opportunities to better understand the muscular dystrophies, advance treatments and improve the lives of affected individuals. Registration: To register, please go to: https://web.cvent.com/event/ebf9b0d2-a61e400b-b8d9-5624d3d51f28/summary. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Room 1255/1265, Rockville, MD 20852 (In-person and Virtual Meeting). Contact Person: Glen Nuckolls, Ph.D., National Institute of Neurological Disorders and Stroke (NINDS), NIH, 6001 Executive Blvd., Rockville, MD 20852, 301–496–5876, glen.nuckolls@nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has procedures at https://www.nih.gov/aboutnih/visitor-information/campus-accesssecurity for entrance into on-campus and offcampus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a governmentissued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Muscular Dystrophy Coordinating Committee website https://mdcc.nih.gov/, where an agenda and any addition information for the meeting will be posted when available. Dated: October 18, 2024. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–24642 Filed 10–23–24; 8:45 am] BILLING CODE 4140–01–P VerDate Sep<11>2014 17:56 Oct 23, 2024 Jkt 265001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required). Date: November 22, 2024. Time: 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G11, Rockville, MD 20892 (Video Assisted Meeting). Contact Person: Barry J. Margulies, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G11, Rockville, MD 20892, (301) 761–7956, barry.margulies@ nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: October 21, 2024. Lauren A. Fleck, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–24745 Filed 10–23–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration HHS Approval of Entities That Certify Medical Review Officers Substance Abuse and Mental Health Services Administration, HHS. AGENCY: PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 ACTION: Notice. This notice publishes a list of the Department of Health and Human Services (HHS) approved Medical Review Officers certification entities. The most recent HHS Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines), effective on October 10, 2023 (Oral Fluid) and February 1, 2024 (Urine), address the role and qualifications of Medical Review Officers (MROs) and HHS approval of entities that certify MROs. DATES: HHS approval is effective October 24, 2024. FOR FURTHER INFORMATION CONTACT: Joshua Hunt, Pharm.D., MPH, LCDR, United States Public Health Service, Area/Regional Pharmacy Consultant, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, Maryland 20857; Telephone: (301) 642–9354; Email: Joshua.hunt@samhsa.hhs.gov. SUPPLEMENTARY INFORMATION: Subpart M—Medical Review Officer (MRO), Section 13.2 of the Mandatory Guidelines, ‘‘How are nationally recognized entities or subspecialty boards that certify MROs approved?’’ states as follows: ‘‘All nationally recognized entities or subspecialty boards which seek approval by the Secretary to certify physicians as MROs for Federal workplace drug testing programs must submit their qualifications, a sample examination, and other necessary supporting examination materials (e.g., answers, previous examination statistics or other background examination information, if requested). Approval will be based on an objective review of qualifications that include a copy of the MRO applicant application form, documentation that the continuing education courses are accredited by a professional organization, and the delivery method and content of the examination. Each approved MRO certification entity must resubmit their qualifications for approval every two years. The Secretary shall publish at least every two years a notice in the Federal Register listing those entities and subspecialty boards that have been approved.’’ HHS has completed its review of entities that certify MROs, in accordance with requests submitted by such entities to HHS. The HHS Secretary approves the following MRO certifying entities that offer MRO certification through examination: American Association of Medical Review Officers (AAMRO), 1506 E. SUMMARY: E:\FR\FM\24OCN1.SGM 24OCN1

Agencies

[Federal Register Volume 89, Number 206 (Thursday, October 24, 2024)]
[Notices]
[Page 84900]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-24745]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; NIAID Clinical Trial Implementation 
Cooperative Agreement (U01 Clinical Trial Required).
    Date: November 22, 2024.
    Time: 1:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3G11, 
Rockville, MD 20892 (Video Assisted Meeting).
    Contact Person: Barry J. Margulies, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3G11, 
Rockville, MD 20892, (301) 761-7956, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: October 21, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-24745 Filed 10-23-24; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.